If you are desperately looking for exposure, I would prefer a defensive sector. Looking at Sanofi in France, the company is still struggling to buy Genzyme Corp. in the U.S.If this deal would be a big positive for the company remains to be seen. What I can see from here is that the stock is moving out of a falling wedge, challenging resistance at EUR 46.5, where you can also find the 50 day moving average. A break of EUR 46.5 would give a clear buy signal.
Traders should not chase the rallies at this point, because chances are high that we witness only a rebound from the obvious support in the S&P at 1040. But keep GDX & SAN on your radar.